scholarly journals ALK and NSCLC: Targeted therapy with ALK inhibitors

10.3410/m3-21 ◽  
2011 ◽  
Vol 3 ◽  
Author(s):  
Bengt Hallberg ◽  
Ruth H. Palmer
Keyword(s):  
Targeted Therapy ◽  
Alk Inhibitors

ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC

2013 ◽  
Vol 8 (1) ◽  
pp. 55-67 ◽  
Author(s):  
Francesca Casaluce ◽  
Assunta Sgambato ◽  
Paolo Maione ◽  
Antonio Rossi ◽  
Carmine Ferrara ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Advanced Nsclc ◽  
Alk Inhibitors

Targeted Therapy for Neuroblastoma: ALK Inhibitors

2013 ◽  
Vol 225 (06) ◽  
pp. 303-308 ◽  
Author(s):  
J. Schulte ◽  
S. Schulte ◽  
L. Heukamp ◽  
K. Astrahantseff ◽  
H. Stephan ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Alk Inhibitors

scholarly journals Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?

ESMO Open ◽  
2018 ◽  
Vol 3 (3) ◽  
pp. e000344 ◽  
Author(s):  
Joseph A Pinto ◽  
Carlos S Vallejos ◽  
Luis E Raez ◽  
Luis A Mas ◽  
Rossana Ruiz ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
Targeted Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Egfr Inhibitors ◽  
Small Cell Lung ◽  
Alk Inhibitors ◽  
Prognostic Variable

BackgroundThere are well-known differences in gender outcome in non-small cell lung cancer (NSCLC) and other cancers. In this work, we evaluated several randomised clinical trials to explore the gender influence in the outcome of patients with NSCLC treated with targeted therapy and immunotherapy.MethodsWe performed a series of meta-analysis to compare the gender outcome in the routine setting for overall survival and progression-free survival (PFS) in phase III randomised clinical trials comparing EGFR inhibitors versus chemotherapy (OPTIMAL, LUX-lung 3, LUX-lung 6, EURTAC, ENSURE and WTJOG); ALK inhibitors versus chemotherapy (ASCEND 4, ASCEND 5, PROFILE 1014 and NCT009323893) and anti-PD1 checkpoint inhibitors versus chemotherapy (CheckMate 017, CheckMate 026, CheckMate 057, KEYNOTE 010 and KEYNOTE 024).ResultsFemale patients with NSCLC have a reduced risk of death compared with men (HR=0.73; 95% CI 0.67 to 0.79; p<0.00001). Women had a better benefit from EGFR inhibitors than men (HR=0.34; 95% CI 0.28 to 0.40; p<0.00001 vs HR=0.44; 95% CI 0.34 to 0.56; p<0.00001, respectively). The benefit from ALK inhibitors was similar for both genders (HR=0.51; 95% CI 0.42 to 0.61; p<0.00001 vs HR=0.48; 95% CI 0.39 to 0.59; p<0.00001, for women and men, respectively). Anti-PD1 inhibitors significantly improved the PFS in male patients when compared with chemotherapy (HR=0.76; 95% CI 0.68 to 0.86; p<0.00001); in contrast, women showed no benefit in 5/5 randomised trials (HR=1.03; 95% CI 0.89 to 1.20; p=0.69).ConclusionsIn this exploratory study, some targeted treatments were influenced by gender. Despite differences in outcomes that could be attributed to different histology, EGFR and smoking status, gender should be evaluated more deeply as prognostic variable in patients with NSCLC.

scholarly journals Which Should Be Used First for ALK-Positive Non-Small-Cell Lung Cancer: Chemotherapy or Targeted Therapy? A Meta-Analysis of Five Randomized Trials

Medicina ◽  
2019 ◽  
Vol 55 (2) ◽  
pp. 29 ◽  
Author(s):  
Yen-Chien Lee ◽  
Chung-Cheng Hsieh ◽  
Yen-Ling Lee ◽  
Chung-Yi Li
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Targeted Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Inhibitors ◽  
The Impact

Background and objectives: Targeted therapy is widely used in the era of precision medicine. Whether the sequence in which targeted therapy and chemotherapy are performed matters, is however not known. We examined the impact of the sequential treatment of targeted therapy and chemotherapy among advanced anaplastic lymphoma kinase (ALK), non-small cell lung cancer (NSCLC) patients. Materials and Methods: Randomized controlled trials comparing the use of ALK inhibitors with chemotherapy were included in this meta-analysis. We estimated the hazard ratios (HRs) and 95% confidence intervals (CI), for progression-free survival (PFS) and overall survival (OS) from a random effects model. Two-sided statistical tests were used to determine the significance of these estimates. Results: In five eligible studies (1404 patients), ALK targeted therapy, in comparison with chemotherapy, had a significantly higher PFS (HR = 0.48; 95% CI, 0.42–0.55), but not significantly higher OS (HR = 0.88; 95% CI, 0.72–1.07). Crossover from chemotherapy to ALK inhibitors was allowed after progression in all trials. The sensitivity analysis of the use of ALK inhibitors as either the first- or second-line treatment, showed improvements in PFS but not in OS. Conclusions: Our results indicate that using targeted therapy first improved PFS, but that the sequence in which the treatments were performed did not cause a significant difference in overall survival.

Lungenkarzinom: Genomisch stratefiziert behandeln: Wohin geht die Entwicklung?

2012 ◽  
Vol 03 (04) ◽  
pp. 184-185
Author(s):  
Christine Vetter
Keyword(s):  
Targeted Therapy

Die „Targeted Therapy” hat in den vergangenen Jahren in vielen Bereichen der Onkologie Fuß gefasst und gewinnt auch beim Lungenkarzinom zunehmend an Boden. Wie sich diese neue Therapierichtung künftig entwickeln kann, war eines der Themen beim diesjährigen Deutschen Krebskongress in Berlin.

Sign in / Sign up

Export Citation Format

Share Document